Vilon: Dosing Protocols

Preclinical Research Status#

Vilon has not been evaluated in clinical trials registered with Western regulatory agencies (FDA, EMA). All dosing information below is derived from preclinical animal studies and Russian bioregulator product marketing. No validated human dosing protocols exist.

Research Dosing in Animal Models#

Lifespan Studies (Khavinson and Anisimov, 2000)#

In the foundational geroprotective studies:

• Species: Female CBA mice
• Route: Subcutaneous injection
• Start age: 6 months of age
• Duration: Chronic (long-term) administration
• Outcomes: Increased physical activity and endurance, decreased body temperature, prolonged lifespan, prevented spontaneous neoplasm development
• Safety: No unfavorable effects on animal development reported

In Vitro Studies#

Vilon has been used in cell culture at various concentrations:

• Thymic cell cultures: Immunomodulatory effects on immune cell differentiation markers
• Lymphocytes from aged donors: Chromatin remodeling (deheterochromatinization) observed
• Mesenchymal stem cells: Gene expression changes in IGF1, FOXO1, TERT, NFkB

Specific in vitro concentrations have varied across studies and are not standardized.

Russian Bioregulator Products#

Vilon capsules have been marketed in Russia as a dietary bioregulator supplement. These products:

• Are not approved by the FDA, EMA, or other Western regulatory agencies
• Have not undergone clinical trials meeting ICH-GCP standards
• Lack published pharmacokinetic data demonstrating oral bioavailability
• May not contain validated quantities of intact vilon dipeptide

Fundamental Bioavailability Questions#

A critical limitation of vilon dosing is the lack of pharmacokinetic data. Key unknowns:

1. Oral absorption: Whether intact vilon dipeptide survives GI digestion and is absorbed intact through intestinal peptide transporters
2. Serum stability: How rapidly vilon is degraded by serum dipeptidases after absorption
3. Tissue distribution: Whether intact vilon reaches target tissues (thymus, lymphoid organs)
4. Dose-response: No dose-response relationship has been characterized in any species
5. Species translation: Mouse doses cannot be directly translated to human equivalent doses

Without answers to these fundamental questions, any human dosing protocol for vilon would be speculative.

Dosing Context#

Vilon belongs to the Anti-Aging category of research peptides. Dosing protocols for Vilon are derived from available clinical trial data. These protocols are provided for research reference only and do not constitute medical advice. Actual dosing decisions should be made by qualified healthcare providers based on individual patient factors.

Research Protocols#

The following dosing protocols have been documented in clinical research for Vilon:

Preclinical Geroprotective Research (Subcutaneous)#

Dose: In CBA mouse studies by Khavinson and Anisimov, vilon was administered subcutaneously starting at 6 months of age. Chronic administration extended lifespan and reduced spontaneous tumor incidence.

Frequency: Chronic subcutaneous injection in preclinical models

Duration: Long-term administration in mouse lifespan studies

Published in Doklady Biological Sciences (2000) and Bulletin of Experimental Biology and Medicine (2000). Mouse doses are not translatable to human dosing. No human PK data exists.

Russian Bioregulator Supplement (Oral Capsules)#

Dose: Vilon has been marketed in Russia as an oral bioregulator supplement in capsule form. Specific dosing recommendations from Russian manufacturers are not validated by Western regulatory standards.

Frequency: Not established by Western clinical trials

Duration: Not established by Western clinical trials

No formal pharmacokinetic studies demonstrating oral bioavailability of intact vilon dipeptide have been published. Efficacy of oral capsule formulations has not been demonstrated in controlled clinical trials.

Reconstitution and Preparation#

Research-grade vilon is supplied as lyophilized powder. Reconstitute in sterile water or appropriate buffer for in vitro or in vivo research use. Follow supplier-specific instructions. Also available as pre-formulated oral capsules from Russian supplement manufacturers.

Storage Requirements#

Store lyophilized peptide at -20 degrees C, protected from light and moisture. Reconstituted solutions should be used promptly or aliquoted and stored at -20 degrees C. Capsule formulations should be stored per manufacturer instructions.

Related Reading#

• Vilon overview and research guide
• Vilon side effects profile
• Vilon research evidence